Mannucci P M
A. Bianchi Bonomi Hemophilia and Thrombosis Center, University of Milano, Italy.
Blood. 1988 Nov;72(5):1449-55.
Desmopressin (1-deamino-8-D-arginine vasopressin, abbreviated DDAVP) is a synthetic analogue of the antidiuretic hormone L-arginine vasopressin. Because it can raise circulating levels of factor VIII coagulant activity (FVIII) and von Willebrand factor and shorten the prolonged bleeding time, DDAVP is established as a nontransfusional form of treatment for mild and moderate hemophilia and von Willebrand disease. Recently, DDAVP has also been purported to be useful for shortening the prolonged skin bleeding times that occur with uremia, cirrhosis, and platelet dysfunctions of various etiologies. Finally, there is evidence from controlled clinical trials that DDAVP can reduce blood loss and transfusion requirements for hemostatically normal individuals undergoing spinal fusion surgery and for patients undergoing cardiopulmonary bypass surgery. The purpose of this report is to review the therapeutic applications of DDAVP in congenital and acquired bleeding disorders and to discuss areas in which further basic and clinical research is needed.
去氨加压素（1-去氨基-8-D-精氨酸加压素，缩写为DDAVP）是抗利尿激素L-精氨酸加压素的合成类似物。由于它能提高凝血因子VIII促凝活性（FVIII）和血管性血友病因子的循环水平，并缩短延长的出血时间，去氨加压素已被确立为治疗轻度和中度血友病及血管性血友病的一种非输血治疗方式。最近，去氨加压素也被认为可用于缩短尿毒症、肝硬化以及各种病因导致的血小板功能障碍所出现的延长的皮肤出血时间。最后，来自对照临床试验的证据表明，去氨加压素可减少接受脊柱融合手术的止血功能正常个体以及接受体外循环手术患者的失血量和输血需求。本报告的目的是回顾去氨加压素在先天性和获得性出血性疾病中的治疗应用，并讨论需要进一步进行基础和临床研究的领域。
